PainReform Ltd Stock

$1.44

2.13% yesterday

Nasdaq, Jun 30, 10:00 pm CET

ISIN

IL0011651580

Symbol

PRFX

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

PainReform Ltd Stock price

$1.44

-1,616.16 99.91% 5Y

Nasdaq, Closing price Mon, Jun 30 2025

+0.03 2.13%

ISIN

IL0011651580

Symbol

PRFX

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Key metrics

Basic

Market capitalization

$2.8m

Enterprise Value

$-1.4m

Net debt

positive

Cash

$4.3m

Shares outstanding

1.5m

Valuation (TTM | estimate)

P/E

negative | negative

P/S

- | -

EV/Sales

- | -

EV/FCF

0.11

P/B

1.14

Financial Health

Equity Ratio

40.31%

Return on Equity

-799.78%

ROCE

-1,319.76%

ROIC

Debt/Equity

0.00

Financials (TTM | estimate)

Revenue

$0.0 | $0.0

EBITDA

$-27.6m | -

EBIT

$-27.6m

Net Income

$-27.4m | $-72.3m

Free Cash Flow

$-12.6m

Growth (TTM | estimate)

Revenue

- | -

EBITDA

-188.39% | -

EBIT

-187.92%

Net Income

-193.47% | -395.75%

Free Cash Flow

-88.79%

Margin (TTM | estimate)

Gross

EBITDA

- | -

EBIT

Net

- | -

Free Cash Flow

EPS

$-60.42

FCF per Share

$-8.59

Short interest

5.88%

Employees

4.00

Rev per Employee

$0.00

As a Free StocksGuide user, you can view scores for all 6,948 stocks worldwide.

Get Started for Free Today

PainReform Ltd Stock Analysis

Unlock Scores for Free

??

6 Analysts have issued a PainReform Ltd forecast:

3x Hold

50%

3x Sell

50%

More details on Analyst Estimates Including Price Targets

6 Analysts have issued a PainReform Ltd forecast:

Hold

50%

Sell

50%

Analyst Estimates with Stock Price Targets

Financial data from PainReform Ltd

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Dec '24		+/- %
Revenue	- -	- 100%
- Direct Costs	- -	- -
Gross Profit	- -	- -
- Selling and Administrative Expenses	4.47 4.47	26% 26% -
- Research and Development Expense	23 23	283% 283% -
EBITDA	-28 -28	188% 188% -
- Depreciation and Amortization	0.02 0.02	0% 0% -
EBIT (Operating Income) EBIT	-28 -28	188% 188% -
Net Profit	-27 -27	193% 193% -

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

PainReform Ltd Stock News

Neutral

PRNewsWire

●

about one month ago

Blade Ranger: Consideration from PainReform Transaction Continues to Mature Following Growth in Software Sales

As a result of increased software sales by the acquirer, and in accordance with the terms of the software business sale agreement, a significant number of zero-exercise-price warrants have matured—Blade Ranger now holds approximately 1 million shares and warrants exercisable at no additional cost TEL AVIV, Israel , May 27, 2025 /PRNewswire/ -- Blade Ranger Ltd. (TASE: BLRN), a company listed on...

Neutral

GlobeNewsWire

●

about 2 months ago

PainReform Launches Strategic AI Pilot with Econergy Using Its Proprietary DeepSolar™ Platform to Optimize One of Romania's Largest Solar Projects

TEL AVIV, Israel, May 07, 2025 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX), today announced the launch of a strategic pilot program with Econergy Renewable Energy Ltd., a leading European independent power producer (IPP). The project will utilize PainReform's proprietary DeepSolar™ platform, an AI-powered optimization solution designed to enhance operational efficiency and energy yield a...

Neutral

GlobeNewsWire

●

3 months ago

PainReform Expands into Home Energy Management Sector, Leveraging DeepSolar's AI-Driven Platform to Address the Growing Solar Optimization Market

TEL AVIV, Israel, April 10, 2025 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX), a clinical-stage specialty pharmaceutical company and developer of AI-powered energy optimization technologies, today announced its official expansion into the rapidly growing Smart Energy Management (SEM) sector. This move follows the successful acquisition of DeepSolar, a cutting-edge provider of AI-driven so...

More PainReform Ltd News

Company Profile

PainReform Ltd. operates as a pharmaceutical company. It develops and markets pharmaceuticals. The firm focuses on developing reformulation of pain therapeutics, PainReform applies its propriety formulation technologies to prolong and enhance efficacy, reduce adverse effects shortening recovery time and reduce the need of augmentation with drugs such as opioids and NSAIDS. The company was founded by Lihu Avitov and Dan Teleman in 2007 and is headquartered in Herzliya, Israel.

Head office	Israel
CEO	Ehud Geller
Employees	4
Founded	2007
Website	painreform.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now